For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
26
views
21
references
 Top references
cited by
1
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      231
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Therapeutic apheresis in peripheral and retinal circulatory disorders

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In microcirculation disorders, the therapeutic apheresis seems to have two different effects. The first, achieved after only a few sessions, is acute, consisting of drastic reduction of blood viscosity and obtained with the use of low-density lipoprotein (LDL) apheresis, rheopheresis, or fibrinogen apheresis. The second effect is long term, or chronic, and needs to be evaluated after a long course of treatment. The mechanisms underlying the chronic effect are still objects of debate and take into account the pleiotropic effects of apheresis. However, it is likely that the acute effect of apheresis mainly influences the functional components of the vascular damage, and so the derived rheological benefit might last only for a short period. The chronic effect, on the contrary, by acting on the morphological alterations of the vascular walls, requires the apheresis treatment to be prolonged for a longer period or even cycles of treatment to be programmed.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: found
          • Article: not found

          Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial.

          M Suckfüll, (2002)
          Sudden sensorineural hearing loss (SSHL) is thought to have many different origins, including disturbances of microcirculation, autoimmune pathology, and viral infection. We aimed to determine whether acute reduction of plasma fibrinogen and serum LDL is effective for treatment of SSHL of suspected vascular origin. Between January, 2000, and June, 2001, we recruited 201 patients with sudden hearing loss from four otorhinolaryngology clinics in Germany. Patients were randomly allocated to single fibrinogen/LDL apheresis or standard treatment (250 mg prednisolone reduced by 25 mg per day, 500 mL 6% hydroxyethyl starch, 400 mg pentoxifylline per day). The primary outcome was recovery of hearing as measured by pure-tone audiometry 48 h after the start of treatment. Secondary outcomes were recovery of hearing 6 weeks after treatment, improvement of speech audiometry, tinnitus, and frequency of side-effects. Analysis was done per protocol. Overall improvement of pure-tone thresholds was slightly but not significantly better in patients given apheresis than in those given standard treatment (difference 7.7, 95% CI -8.2 to 23.6). However, the mean sound level at which 50% of recorded digits were recognised was significantly lower after 48 h in the apheresis group (21.6 dB, SD 20.8) than in the standard group (29.3 dB, 29.4; p=0.034). After 6 weeks, the mean 50% speech perception was at 13.6 dB (SD 14.3) in the apheresis group and at 20.8 dB (25.4) in those on standard treatment (p=0.059). At 48 h, in patients with plasma fibrinogen concentrations of more than 295 mg/dL, speech perception was improved much more in those on apheresis (15.3 dB, 17.3) than in those on standard treatment (6.1 dB, 10.4; p=0.005). A single fibrinogen/LDL apheresis lasting for 2 h could be used as an alternative to conventional infusion treatment and prednisolone for 10 days. Patients with a plasma fibrinogen of more than 8.68 micromol/L improve much better when treated with apheresis, especially if serum LDL concentrations are also raised.
          Article 0 comments Cited 30 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART).

            Takashi Honda, K Fukami, Katsuhiko Hiramori … (2002)
            We sought to assess the effects of low density lipoprotein (LDL)-apheresis (LDL-A) for regression of coronary plaque in familial hypercholesterolemia (FH), we set up a one-year follow-up multicenter trial using coronary angiography and intravascular ultrasound (IVUS). It is still unclear whether aggressive lipid-lowering therapy by LDL-A leads to the regression of coronary plaque in patients with FH. Eighteen patients with FH were assigned to one of two groups: medication + LDL-A (LDL-A group, n = 11) and medication only (medication group, n = 7). Total cholesterol, triglycerides, high density lipoprotein cholesterol and LDL cholesterol were measured in all subjects at the outset of treatment (baseline) and every three months thereafter. Coronary angiography and IVUS were performed at the outset and after the one-year follow-up period to measure minimal lumen diameter (MLD) by coronary angiogram and plaque area (PA) by IVUS. The LDL-A group showed 28.4% reduction in total cholesterol (from 275 +/- 27 mg/dl to 197 +/- 19 mg/dl) and 34.3% reduction in LDL cholesterol (from 213 +/- 25 mg/dl to 140 +/- 27 mg/dl) after one-year follow-up, while the medication group showed no changes in cholesterol levels. There were significant interactions between both treatments in total cholesterol (p = 0.0001), LDL cholesterol (p = 0.0001), MLD (p = 0.008) and PA (p = 0.017) using two-way repeated-measures analysis of variance by the SAS system (SAS Institute Inc., Cary, North Carolina). Significant differences were seen in net change in MLD (p = 0.004) and PA (p = 0.008) during the one-year follow-up period between both groups. These results suggest that aggressive lipid-lowering therapy using the combination of LDL-A and lipid-lowering drugs may induce regression of coronary atherosclerotic plaque in FH patients.
            Article 0 comments Cited 20 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Rheopheresis for idiopathic sudden hearing loss: results from a large prospective, multicenter, randomized, controlled clinical trial.

              Walter Lehmacher, , Ralph Mösges … (2009)
              Idiopathic sudden hearing loss (ISHL) has been suggested to precipitate as final common pathway of microcirculatory impairment of the inner ear associated with a variety of etiologies and characterized by a local hyperviscosity syndrome in cochlear vessels. Therefore, we investigated the effect of Rheopheresis, a method of therapeutic apheresis reducing plasma viscosity and improving microcirculation on hearing recovery. Patients were randomly assigned to receive two Rheopheresis treatments, or treatment according to current German guidelines consisting either of i.v. corticosteroids (methylprednisolon 250 mg for 3 days and subsequent oral dosing with tapering to zero) or i.v. hemodilution (500 mL 6% hydroxyethyl starch plus 600 mg pentoxifylline per day), each applied for 10 days. The primary outcome parameter was absolute recovery of hearing as measured by pure tone audiometry 10 days after the start of treatment. Secondary outcomes were recovery of hearing at day 42, the improvement of speech audiometry, tinnitus and feeling of pressure and the frequency of adverse events. In total, 240 patients with sudden hearing loss were enrolled from otorhinolaryngological departments at hospitals as well as out-patient clinics in Germany. Analysis was performed for the intention-to-treat as well as per protocol population. Mean absolute recovery of hearing on day 10 within the intention-to-treat population (ITT, n = 193) was 23.95 dB (SD 15.05) in the Rheopheresis group and 24.29 dB (SD 15.48) in the control group. Equal efficacy of Rheopheresis and tested standard treatments was demonstrated (P = 0.00056). Single Rheopheresis led to a higher recovery of hearing after 48 h in patients with high plasma viscosity (>1.8 mPas s; P = 0.029) or high total protein (>74 g/dL; P = 0.02). However, an overall good recovery of ISHL was observed with none of the tested therapies being superior regarding the primary outcome parameter. Improvement of health-related quality of life as documented by the SF36 was higher in the Rheopheresis group, exhibiting a significant difference for the physical summary scale at the final follow-up at day 42 (P = 0.006). In conclusion, Rheopheresis proved to be an effective treatment option within the ENT armamentarium for ISHL. Two Rheopheresis treatments within 3 days lasting for about 2 h each could be used to replace a 10-day infusion regimen, especially in patients who desire fast recovery from acute hearing loss. Also, this may be a second line treatment option for patients refractory to i.v. corticosteroids or hemodilution.
              Article 0 comments Cited 17 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                : a.ramunni@nephro.uniba.it
                Journal
                Journal ID (nlm-ta): Clin Res Cardiol Suppl
                Journal ID (iso-abbrev): Clin Res Cardiol Suppl
                Title: Clinical Research in Cardiology Supplements
                Publisher: Springer-Verlag (Berlin/Heidelberg )
                ISSN (Print): 1861-0706
                ISSN (Electronic): 1861-0714
                Publication date (Electronic): 25 February 2012
                Publication date PMC-release: 25 February 2012
                Publication date (Print): June 2012
                Volume: 7
                Issue: Suppl 1
                Pages: 41-44
                Affiliations
                [1 ]Section of Nephrology, Department Emergency and Organ Transplantation, University of Bari, Bari, Italy
                [2 ]“C Poma” Hospital, Mantova, Italy
                [3 ]Policlinico Universitario Consorziale, 70124 Bari, Italy
                Article
                Publisher ID: 45
                DOI: 10.1007/s11789-012-0045-7
                PMC ID: 3374102
                PubMed ID: 22528133
                SO-VID: 8a1ff88a-b2a3-4ba4-bddd-18477fef5688
                Copyright © © The Author(s) 2012
                History
                Categories
                Subject: Article
                Custom metadata
                issue-copyright-statement © Springer-Verlag 2012

                ScienceOpen disciplines: Cardiovascular Medicine
                Keywords: microcirculation disorders,peripheral arterial disease,rheopheresis,ldl apheresis
                Data availability:
                ScienceOpen disciplines: Cardiovascular Medicine
                Keywords: microcirculation disorders, peripheral arterial disease, rheopheresis, ldl apheresis

                Comments

                Comment on this article

                scite_

                Similar content231

                See all similar

                Cited by1

                See all cited by

                Most referenced authors126

                See all reference authors